Technological Leadership in Pharmaceutical Innovation: Ensuring Patient Access and Global Market Sustainability

Technological leadership in pharmaceutical innovation is one of the key focuses of Russia’s national development. Achieving this goal requires clear criteria for selecting technological platforms that embody the ‘nosology–biotarget–technology’ triad when localizing the full production cycle of innovative drugs. In addition, new mechanisms are needed to facilitate the transfer of technological innovations from related industries, as well as to provide key regulatory and financial support measures for the development, manufacturing, and market launch of pharmaceutical innovations, both for domestic use and for international markets. State strategies and projects contain specific provisions on systemic support for this strategic goal of innovative dominance on the global pharmaceutical market based on the coordinated efforts of regulatory bodies, development institutions, domestic companies, and scientific centres. An interagency coordinating council has been established to promote the effective implementation of collaborative initiatives and foster the development of domestic pharmaceutical innovations. One of its key objectives is to create an environment that is conducive to promising innovative drug developments that are projected to generate RUB 100 billion in government procurements by 2030 and RUB 300 billion by 2036. What successful practices does Russia currently have for supporting an innovation-driven path of development within the pharmaceutical industry? What conditions are needed for the development of world-class domestic innovative medicines? How can we ensure the coordinated actions of key stakeholders in the innovation process? Which specific programmes and projects need to be implemented for Russia to become a full-fledged member of the global community of pharmaceutical innovation exporters, while simultaneously ensuring a high level of domestic pharmaceutical security?